CA3122029A1 - Carborane compounds, carborane analogs, and methods of use thereof - Google Patents

Carborane compounds, carborane analogs, and methods of use thereof Download PDF

Info

Publication number
CA3122029A1
CA3122029A1 CA3122029A CA3122029A CA3122029A1 CA 3122029 A1 CA3122029 A1 CA 3122029A1 CA 3122029 A CA3122029 A CA 3122029A CA 3122029 A CA3122029 A CA 3122029A CA 3122029 A1 CA3122029 A1 CA 3122029A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
alkyl
compound
alkylaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3122029A
Other languages
English (en)
French (fr)
Inventor
Christopher Charles COSS
Chad BENNETT
Jeffrey Patrick
Dasheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CA3122029A1 publication Critical patent/CA3122029A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3122029A 2018-12-03 2019-12-03 Carborane compounds, carborane analogs, and methods of use thereof Pending CA3122029A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862774688P 2018-12-03 2018-12-03
US62/774,688 2018-12-03
US201962798713P 2019-01-30 2019-01-30
US201962798711P 2019-01-30 2019-01-30
US201962798710P 2019-01-30 2019-01-30
US62/798,711 2019-01-30
US62/798,710 2019-01-30
US62/798,713 2019-01-30
PCT/US2019/064228 WO2020117799A1 (en) 2018-12-03 2019-12-03 Carborane compounds, carborane analogs, and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3122029A1 true CA3122029A1 (en) 2020-06-11

Family

ID=70974874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3122029A Pending CA3122029A1 (en) 2018-12-03 2019-12-03 Carborane compounds, carborane analogs, and methods of use thereof

Country Status (7)

Country Link
US (2) US20220040210A1 (enExample)
EP (1) EP3890750A4 (enExample)
JP (1) JP7644006B2 (enExample)
CN (1) CN113347979B (enExample)
AU (1) AU2019393785A1 (enExample)
CA (1) CA3122029A1 (enExample)
WO (1) WO2020117799A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515580A (zh) * 2020-03-11 2022-12-23 俄亥俄州国家创新基金会 使用碳硼烷和碳硼烷类似物调节t细胞活化的方法
WO2023239764A1 (en) * 2022-06-08 2023-12-14 Ohio State Innovation Foundation Methods and compositions for treating lupus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043016A1 (en) * 1999-01-22 2000-07-27 Institute Of Medicinal Molecular Design. Inc. DICARBA-closo-DODECABORANE DERIVATIVES
KR100884489B1 (ko) * 2007-02-21 2009-02-18 원광대학교산학협력단 1,3,5-트리아진-4-일-디카르보-클로소-도데카보란 유도체,이의 제조방법 및 이를 포함하는 약학적 조성물
ES2700141T3 (es) * 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
DE102007038930B4 (de) * 2007-08-13 2013-12-05 Universität Leipzig Neue chemische Verbindung und deren Verwendung in der Medizin, insbesondere für die Verwendung in der Tumortherapie
JP2010208996A (ja) * 2009-03-11 2010-09-24 Okayama Univ 置換フェニルプロピオン酸誘導体を含有する医薬組成物
CZ2011676A3 (cs) * 2011-10-24 2013-05-02 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Inhibitory karbonické anhydrasy, zpusob jejich prípravy
CN108884124A (zh) * 2015-09-17 2018-11-23 俄亥俄州创新基金会 碳硼烷化合物及其使用方法

Also Published As

Publication number Publication date
WO2020117799A1 (en) 2020-06-11
CN113347979B (zh) 2024-08-16
CN113347979A (zh) 2021-09-03
EP3890750A4 (en) 2022-08-10
AU2019393785A1 (en) 2021-06-17
AU2019393785A2 (en) 2021-06-24
US20250281515A1 (en) 2025-09-11
JP2022510008A (ja) 2022-01-25
JP7644006B2 (ja) 2025-03-11
US20220040210A1 (en) 2022-02-10
EP3890750A1 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
US11771712B2 (en) Carborane compounds and methods of use thereof
US20250281515A1 (en) Carborane compounds, carborane analogs, and methods of use thereof
US9783513B2 (en) STAT3 inhibitors and their anticancer use
US20140288077A1 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
JP2013537535A (ja) Ｓｔａｔタンパク質の阻害剤としての、置換２−ヒドロキシ−４−（２−（フェニルスルホンアミド）アセトアミド）安息香酸類似体
ES2938278T3 (es) Compuestos como moduladores de la señalización de TLR2
KR20220044782A (ko) Acc 억제제로서의 티에노피리미딘 유도체 및 이의 용도
US20140315956A1 (en) Small molecule inhibitors of il-6 and uses thereof
WO2023141538A1 (en) Compositions comprising lipid compounds and methods of making and use thereof
WO2023086365A1 (en) Compositions comprising amino lipid compounds and methods of making and use thereof
US8871983B2 (en) Lipid compounds for suppression of tumorigenesis
US20250188098A1 (en) Carborane compounds and methods of use thereof
HK40053312B (zh) 碳硼烷化合物、碳硼烷类似物及其使用方法
HK40053312A (en) Carborane compounds, carborane analogs, and methods of use thereof
HK1261921A1 (en) Carborane compounds and methods of use thereof
HK1261921B (en) Carborane compounds and methods of use thereof
US20250289837A1 (en) Mitochondriotropic heteroaryl benzamide potassium channel kv1.3 inhibitors
HK40126954A (zh) 募集cereblon的bcl-xl/bcl-2双重降解剂

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240718